The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The impact of IGHV repertoire after ibrutinib-containing regimens in patients enrolled in TRIANGLE
In this video, Simone Ragaini, MD, University of Turin, Turin, Italy, briefly discusses the impact of IGHV repertoire after ibrutinib-containing regimens in younger patients with mantle cell lymphoma (MCL) enrolled in the TRIANGLE trial (NCT02858258). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We presented here the Multiple study about TRIANGLE patients, about younger mantle cell lymphoma patients, and we showed that some specific IGHV rearrangements can be associated with the prognosis of mantle cell lymphoma and we show that ibrutinib can add some immune modulation in these patients and can change the prognosis of some specific rearrangements. And we also show that mutated patients, I mean patients with homology less than 97%, can be associated with improved outcomes...
We presented here the Multiple study about TRIANGLE patients, about younger mantle cell lymphoma patients, and we showed that some specific IGHV rearrangements can be associated with the prognosis of mantle cell lymphoma and we show that ibrutinib can add some immune modulation in these patients and can change the prognosis of some specific rearrangements. And we also show that mutated patients, I mean patients with homology less than 97%, can be associated with improved outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
